☆ 4.1 Article

WHO should accelerate, not stall, rectal artesunate deployment for pre-referral treatment of severe malaria

TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE (2023)

Prereferral rectal artesunate and referral completion among children with suspected severe malaria in the Democratic Republic of the Congo, Nigeria and Uganda

Nina C. Brunner et al.

Summary: The use of prereferral rectal artesunate (RAS) may decrease the likelihood of referral completion in children. Barriers to referral completion need to be addressed to ensure the effective implementation of community-based programs. Alternative effective treatment options should be provided to children unable to complete referral.

BMJ GLOBAL HEALTH (2022)

添加到收藏夹

Editorial Material Public, Environmental & Occupational Health

Stopping prereferral rectal artesunate - a grave error

James A. Watson et al.

BMJ GLOBAL HEALTH (2022)

添加到收藏夹

Article Medicine, General & Internal

Effectiveness of rectal artesunate as pre-referral treatment for severe malaria in children under 5 years of age: a multi-country observational study

Manuel W. Hetzel et al.

Summary: This study examined the effectiveness of pre-referral rectal artesunate treatment implemented in the Democratic Republic of the Congo (DRC), Nigeria, and Uganda. In Nigeria, the case fatality rate was higher post-roll-out of RAS, while it remained stable in DRC and Uganda. Only in Uganda, children who received RAS were less likely to be dead or sick at follow-up.

BMC MEDICINE (2022)

添加到收藏夹

Editorial Material Medicine, General & Internal